Michael A. PostowMD
Michael Postow, MD is a medical oncologist on faculty in the Melanoma and Immunotherapeutics Oncology Service at Memorial Sloan Kettering Cancer Center. He was the principal investigator of a clinical trial which led to FDA approval of the nivolumab + ipilimumab immunotherapy combination to treat melanoma and is currently leading other studies testing immunotherapy combinations for patients with advanced melanoma and other cancers. He has published first or senior author publications related to immunotherapy and melanoma care in the New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology. He enjoys traveling to speak about topics related to research and treatment of advanced melanoma.